Dainippon Sumitomo Launches Parkinson’s Disease Drug Trerief In Japan
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Dainippon Sumitomo Pharma launched March 13 Trerief (zonisamide), which was approved in Japan in January to treat movement disorders such as akinesia and muscle rigidity associated with Parkinson's disease. DSP estimates that there are 150,000 to 160,000 patients in Japan, and that sales for the first year will be around ¥1.1 billion, with a potential rise to ¥5.4 billion by 2017. Zonisamide was previously approved as an antiepileptic drug and sold under the name Excergran. (Click here for more - Japanese language